# Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

Study · id `cardio:ct-nct04502017` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04502017](<https://clinicaltrials.gov/study/NCT04502017>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04502017

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 360 participants.

## Technical summary

Registry record NCT04502017. Randomized; no masking; primary purpose prevention. Start 2020-08-05 (actual); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT04502017, source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)
- Started: 2020-08-05 (actual) (ClinicalTrials.gov record NCT04502017, source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04502017, source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT04502017, source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04502017, source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04502017-2020-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
- Acronym: FADE-DRT
- Condition: Device-Related Thrombosis
- Condition: Atrial Fibrillation
- Condition: Left Atrial Appendage Occlusion
- Intervention (Drug): ASA plus Clopidogrel
- Intervention (Drug): Genetic-Tailored AntiThrombotic Strategy
- Intervention (Drug): Half-Dose of novel OAC
- Lead sponsor: Texas Cardiac Arrhythmia Research Foundation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Texas Cardiac Arrhythmia Research Foundation (`cardio:org-texas-cardiac-arrhythmia-research-foundation`)

## Provenance

Content hash: 04b9868a143620d8b523ea80df2551a8ff278970ae790f9a56e408585b4b99d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
